Psychosocial risk markers for new onset irritable bowel syndrome – Results of a large prospective population-based study

por Nicholl, B.I., Halder, S.L., Macfarlane, G.J., Thompson, D.G., O’Brien, S., Musleh, M., McBeth, J.
Publicado 2008

Characterization of Serotonin Signaling Components in Patients with Inflammatory Bowel Disease

por Shajib, Md Sharif, Chauhan, Usha, Adeeb, Salman, Chetty, Yeshale, Armstrong, David, Halder, Smita L S, Marshall, John K, Khan, Waliul I
Publicado 2019

Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers With Biopsy Results

por Kyle, Barry D, Agbor, Terence A, Sharif, Shajib, Chauhan, Usha, Marshall, John, Halder, Smita L S, Ip, Stephen, Khan, Waliul I
Publicado 2020

A66 THE IMPACT OF A MULTIDISCIPLINARY ADOLESCENT AND YOUNG ADULT (AYA) INFLAMMATORY BOWEL DISEASE (IBD) ON CLINIC NO SHOW RATES

por Sharma, R, Halder, S L, Zachos, M, Radoja, C, Grant, C, Chauhan, U, Brackenridge, E, Issenman, R, Sherlock, M, Dowhaniuk, J K, Pai, N, Brill, H, Ratcliffe, E, Narula, N, Marshall, J, Prowse, K
Publicado 2022